CBU
ABUS icon

CIBC Bancorp USA’s Arbutus Biopharma ABUS Stock Holding History

CIBC Bancorp USA’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$73.3K Buy
+16,138
New +$59.3K ﹤0.01% 1386

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CIBC Bancorp USA's ABUS Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Arbutus Biopharma (ABUS) in Q3 2025: 16,138 shares worth $73.3K. The stake represents ﹤0.01% of the portfolio and ranks #1386 among its holdings.

166 funds tracked by Wall St. Rank hold ABUS as of Q3 2025.

  • CIBC Bancorp USA held 16,138 shares of Arbutus Biopharma worth $73.3K as of Q3 2025.
  • Arbutus Biopharma was a new CIBC Bancorp USA position in Q3 2025.
  • Arbutus Biopharma made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1386 holding.
  • 166 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.